Last updated: March 2, 2026
What is the drug associated with NDC 67386-0315?
NDC 67386-0315 is associated with Ralinepag, an experimental prostacyclin receptor agonist developed for pulmonary arterial hypertension (PAH). It is designed to improve pulmonary blood flow and reduce pulmonary vascular resistance.
What is the current regulatory status?
As of the latest data, Ralinepag is in Phase 3 clinical trials, according to the FDA's database. It has not received FDA approval or clearance for commercial distribution. No approved indication exists yet.
Market Landscape
Disease prevalence and unmet needs
Pulmonary arterial hypertension affects approximately 15-50 cases per million worldwide, with higher prevalence in specialized centers. The primary goal of therapies like Ralinepag is to reduce symptoms, improve functional capacity, and delay disease progression.
Competitors and pipeline drugs
| Drug Name |
Class |
Approval Status |
Market Share |
Notable Features |
| Epoprostenol (Flolan) |
Prostacyclin infusion |
Approved |
High |
Proven efficacy; invasive administration |
| Treprostinil (Remodulin) |
Prostacyclin analogue |
Approved |
High |
Subcutaneous/intravenous/inhaled formulations |
| Selexipag (Uptravi) |
Oral prostacyclin receptor agonist |
Approved |
Growing |
Oral administration; established market presence |
| Riociguat (Adempas) |
Soluble guanylate cyclase stimulator |
Approved |
Moderate |
Different mechanism; used in combination therapy |
| Macitentan (Opsumit) |
Endothelin receptor antagonist |
Approved |
Moderate |
Oral; used in PAH management |
Estimated market size
The global PAH drug market was valued at approximately USD 3.2 billion in 2022, with an expected compound annual growth rate (CAGR) of 6%-8% through 2030[1]. Ralinepag targeting the same niche could capture 5%-15% of this market post-approval, depending on efficacy and safety profiles.
Entry barriers
- Lengthy regulatory approval process.
- Existing competition with established therapies.
- Need for demonstration of superior efficacy or safety.
- High R&D and commercialization costs.
Price projections
Current market prices for PAH drugs
| Drug (per month) |
Price Range (USD) |
| Epoprostenol (Flolan) |
15,000 - 20,000 |
| Treprostinil (Remodulin) |
10,000 - 18,000 |
| Selexipag (Uptravi) |
5,000 - 7,000 |
| Riociguat (Adempas) |
4,000 - 6,000 |
| Macitentan (Opsumit) |
3,500 - 5,000 |
Projected pricing for Ralinepag
- Pre-approval phase: Pricing likely to align with existing prostacyclin receptor agonists, approximately USD 6,000-8,000 monthly per patient.
- Post-approval: Market entry price could be set at USD 5,500-7,000, considering competition and manufacturing costs.
- Premium positioning: If Ralinepag demonstrates superior safety or convenience over existing therapies, a premium price of USD 8,000-10,000 may be possible.
Discount and reimbursement considerations
Pricing strategies will depend on payer negotiations, regulatory policies, and formulary inclusion. Co-payments and patient assistance programs could influence net revenue.
Financial outlook and investment implications
- Early-stage involvement could realize value if approval occurs within 2-3 years.
- Price premium depends on clinical trial outcomes; approval delays or negative results may reduce projected revenues.
- Licensing or partnership deals might be pursued for commercialization, impacting revenue sharing.
Key factors impacting price and market share
- Demonstration of clinical superiority over existing options.
- Safety profile and tolerability.
- Ease of administration (oral vs. infusion).
- Regulatory approval timelines.
Summary table: Forecasted market entry and pricing
| Timeline |
Market Entry |
Estimated Monthly Price (USD) |
Market Penetration Potential |
| Year 2024 |
Likely |
6,000 - 8,000 |
5% - 10% |
| Year 2025-2026 |
Post-approval |
5,500 - 7,000 |
10% - 15% |
Key Takeaways
- NDC 67386-0315 corresponds to Ralinepag, in late-stage development for PAH.
- The drug faces significant clinical and regulatory hurdles before market entry.
- Pricing will likely mirror existing prostacyclin receptor agonists initially, with potential premium positioning based on efficacy and safety.
- The overall PAH market is growing, with a valuation of USD 3.2 billion in 2022 and a 6%-8% CAGR.
- Market success depends on clinical data, regulatory progress, and competitive dynamics.
FAQs
-
What is the current regulatory status of Ralinepag?
Ralinepag is in Phase 3 clinical trials; it has not received FDA approval yet.
-
What are the main competitors in the PAH drug market?
Epoprostenol, treprostinil, selexipag, riociguat, and macitentan.
-
How is the market size expected to evolve?
The global PAH drug market is projected to grow at 6%-8% CAGR, reaching potentially USD 5 billion by 2030.
-
What factors will influence the drug's pricing post-approval?
Clinical efficacy, safety profile, administration route, and competitive positioning.
-
When could Ralinepag realistically enter the market?
Approval could occur in 2024 or 2025, assuming positive trial outcomes and regulatory progress.
References
[1] GlobalData. (2022). Pulmonary arterial hypertension therapeutics market analysis. Retrieved from https://www.globaldata.com
